Friday, March 20, 2026Fri, Mar 20, 2026

TrendingNews.today

S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|

S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|

HealthUnited States1 sourcesNeutral

Altesa BioSciences' Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026

Altesa advancing clinical development of vapendavir through its Phase 2B Cardinal Study COLLEGE PARK, Ga., March 19, 2026 /PRNewswire/ -- Altesa BioSciences will present novel data regarding the mechanisms of action and anti-viral coverage of vapendavir and its newly discovered active...

CP

cision pr newswire

via Pr Newswire

March 19, 2026 | 12:00 PM UTCUpdated 2h ago

Share Read original

Read the full article at Pr Newswire →

Altesa BioSciences' Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Comments

0 comments

Be respectful and constructive.

Loading comments...

Topology Helps Build More Robust Photonic Networks - University of Pennsylvania

Uber, Rivian announce $1.25 billion deal for 50,000 robotaxis

Related Articles

Malaysia Bourse May Test Support At 1,700 Points

Unknown-2h ago-2 sources

Soft Start Anticipated For South Korea Shares

Unknown-3h ago-2 sources

Treasuries Close Lower After Recovery Attempt Falters

Unknown-6h ago-1 sources